Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, P.R. China.
Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, P.R. China.
Crit Rev Microbiol. 2024 Sep;50(5):631-652. doi: 10.1080/1040841X.2023.2247493. Epub 2023 Sep 11.
The oral cavity contains a site-specific microbiota that interacts with host cells to regulate many physiological processes in the human body. Emerging evidence has suggested that changes in the oral microbiota can increase the risk of lung cancer (LC), and the oral microbiota is also altered in patients with LC. Human and animal studies have shown that oral microecological disorders and/or specific oral bacteria may play an active role in the occurrence and development of LC through direct and/or indirect mechanisms. These studies support the potential of oral microbiota in the clinical treatment of LC. Oral microbiota may therefore be used in the prevention and treatment of LC and to improve the side effects of anticancer therapy by regulating the balance of the oral microbiome. Specific oral microbiota in LC may also be used as screening or predictive biomarkers. This review summarizes the main findings in research on oral microbiome-related LC and discusses current challenges and future research directions.
口腔中存在特定的微生物群，与宿主细胞相互作用，调节人体许多生理过程。新出现的证据表明，口腔微生物群的变化会增加肺癌 (LC) 的风险，而 LC 患者的口腔微生物群也发生了改变。人体和动物研究表明，口腔微生态失调和/或特定的口腔细菌可能通过直接和/或间接机制在 LC 的发生和发展中发挥积极作用。这些研究支持口腔微生物群在 LC 临床治疗中的潜力。口腔微生物群可能通过调节口腔微生物组的平衡，用于 LC 的预防和治疗，并改善抗癌治疗的副作用。LC 中的特定口腔微生物群也可用作筛选或预测生物标志物。本综述总结了与口腔微生物组相关的 LC 研究的主要发现，并讨论了当前的挑战和未来的研究方向。
